Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, both in vitro and in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.
Introduction
Apoptosis is a complex program of cellular suicide, and inhibition of apoptosis is considered to be an important mechanism involved in cancer formation and progression by extending the life span of cells and thus favoring the accumulation of transforming mutations [ 1] . Survivin is a member of the inhibitor-ofapoptosis (IAP) family that blocks apoptosis pathways by inhibiting effector caspase molecules [2] . Whilst highly expressed in fetal tissues, survivin is generally not detectable in normal adult tissues with the exception of thymus and placenta [2] . In contrast, expression of survivin was reported in the majority of malignant tumors arising from the lung [3] , the prostate [4], the skin [5] , the colon [6] , the pancreas [7] , the breast [8] , the stomach [9] , the esophagus [10] and from hematopoietic cells [11] . Interestingly, expression of survivin was shown to be associated with an unfavorable prognosis of some cancers [3, 10, 11] , supporting the idea that apoptosis inhibition may contribute to tumor progression.
Recent data suggest that a significant fraction of human astrocytomas may also express survivin. Using semi-quantitative Western-blot analysis on frozen tumor tissues, Chakravarti et al. [12] reported that 80% of glioblastoma and 39% of not grade IV astrocytoma samples were indeed positive for survivin expression.
However, this approach does not clarify whether tumor cells themselves express survivin and to what extent non tumoral cells such as endothelial cells or infiltrating lymphocytes might contribute to the Western positivity. This is an important issue to explore considering that activated lymphocytes have recently been shown to express survivin [13] . Here, we provide evidence that glioma ceils express survivin both in vitro and in vivo. Furthermore, survivin expression is not restricted to the astrocytic lineage, since most meningiomas and schwannomas are also survivin positive.
Materials and methods

Patients
Peripheral blood samples and tumor biopsies were collected during surgery from 76 patients with brain tumor at the Geneva University Hospital from March 1995 to February 2002. No prior treatment was administered before surgery, except in one case (Ge 133). There were 46 males and 30 females with a mean age of 48.7 years (range: 13-80 years) ( Table 1) .
Tumor cell lines
Melanoma cell line A375 and K562 cell line (a human erythroleukemia cell line) were obtained from ATCC. Human astrocytoma cell lines were derived from tumor biopsies (7 glioblastomas and 1 anaplastic astrocytoma) and maintained in culture as previously described [14] .
Detection of survivin mRNA
Total RNA from frozen tumor and epileptic brain biopsies or from 10 6 cells of tumor cell lines was isolated using RNeasy midi kit or RNeasy mini kit respectively (Qiagen, Hilden, Germany) following manufacturer's recommendations. RNA concentration was determined using spectrophotometry. Total RNA (1 txg) was reverse transcribed using Supersript II (Invitrogen, Groningen, The Netherlands). 10% of the complementary cDNA was used for the PCR. PCR was done using Ready Mix TM PCR reaction mix (Sigma, Buchs, Switzerland) in a final volume of 25 ~1 containing 1 ttM of each 5' and 3' primers (forward and reverse primers). The primer pair used for the detection of survivin was: 5'CACCGCATCTCTACATrCAAG 3' (forward primer); 5'GAAGTGGTGCAGCCACTCTG3' (reverse primer). PCR conditions were as follows: 1 min at 94~ of initial denaturation, followed by 30 cycles of amplification (30 s at 94~ 30 s at 58~ 30 s at 72~ and a final extension step of 10 min at 72~
To check the quality of the cDNA, human /3-actin cDNA amplification was performed. PCR products were resolved on a 1% agarose gel and stained with ethidium bromide. The melanoma cell line A375 was used as positive control. The generated PCR products were verified by sequencing.
Western blot
Human K562 cell line, human astrocytoma cell lines, Flu cytotoxic T cell lymphocytes (CTLs) (directed against M1 peptide: 58-66) and peripheral blood mononuclear cells (PBMC) were used for Western-blot analysis. Briefly, 106 cells were lysed in a lysis buffer containing 25 mM Tris-HC1 pH 7.5, 75 mM NaC1, 0.5% Nonidet P40, 0.25 % sodium deoxycholate, 0.05 % SDS and the complete protease inhibitors set (Roche Diagnostics, Mannheim, Germany). The samples were denatured in 2x SDS buffer at 95~ for 5 rain then separated on a 10% SDS-polyacrylamide gel (SDS-PAGE) and transferred onto nitrocellulose membrane. Filters were incubated with an anti-human survivin antibody (R&D Systems, Abingdon, United Kingdom) followed by horseradish peroxidase-conjugated antirabbit immunogloblin and developed using chemoluminescence detection kit (Amersham, Uppsala, Sweden).
lmmunohistochemistry
A rabbit polyclonal IgG anti-human survivin antibody (R&D system) was used to detect human survivin on brain tumor histological sections. Normal rabbit IgG was used as a negative control (R&D systems). For immunohistochemical detection, the standard avidinbiotin peroxydase complex technique was carried out by using an LSAB Kit (Dako, Glostrup, Denmark). Sections (3 ktm) were deparaffinized and rehydrated, endogenous peroxydase was quenched with 0.6% H202 and 0.1% sodium azide (Sigma). Antigen retrieval was done by pressure cooking: slides were bathed in a 10 -2 M sodium citrate buffer for 3 min. Sections were then incubated overnight at 4~ with the corresponding antibody at a concentration of 2 I~g/ml after a pre-incubation step of 15 min in a 1/10 normal swine serum (Dako). Biotynilated anti-rabbit immunogloblin and streptavidin conjugated to horseradish peroxydase were then added. Finally, 3,3'-diaminobenzidine was used for color development, and hemalun was used for counterstaining.
Results
Survivin expression was first investigated at the mRNA level using RT-PCR on 76 tumor biopsies. As illustrated in Figure 1A for (Table 1) , including meningioma and schwannoma. Survivin mRNA was neither detected in non-tumoral brain ( Figure 1D ), nor in the contralateral brain hemisphere of tumorburdened patient (data not shown). However, this type of analysis could not discriminate the cell type expressing survivin in vivo. Thus, we analyzed a series of human astrocytoma cell lines and showed that tumor cells express survivin at the mRNA ( Figure 1B ) and protein ( Figure 2A ) level. Recent data by others [13] suggested that activated T cells might express survivin in some circumstances. The extent to which infiltrating lymphocytes might contribute to the positive signals observed in tumor biopsies was thus an important issue to address. Whilst survivin mRNA was detectable in most PBMC samples from astrocytoma patients and healthy donors ( Figure 1C ), the protein was not detected by Westernblot analysis ( Figure 2B ). This indicates that tumor infiltrating lymphocytes play a minor role (if any) in survivin expression by ex vivo samples.
To confirm protein expression by tumor cells, immunohistochemical analysis was performed. As illustrated in Figure 3 , we observed positively stained tumor cells in each specimen from all types of human brain tumors analyzed (glioblastoma, grade III astrocytoma, schwannoma, meningioma). Interestingly, positive cells showed atypical nucleus and were larger than lymphocytes, whilst perivascular lymphocytes and hyperplasic endothelia were negative. The number of positively stained cells was highly variable, even among samples with the same histological diagnosis. This indicates that further analyses are required in order to investigate for possible correlation with the tumor type, the histological grade and the clinical outcome of the patients. Survivin is expressed by astrocytoma cell lines but not by PBMC from astrocytoma patients and healthy individual. The presence of survivin protein was checked by western blotting in glioblastoma cell lines as illustrated for Ge258 in (A), and in PBMC from glioblastoma patients (Ge224) and from the flu CTLs of an healthy donor (B). K562 cell line was used as a positive control. The negative control used corresponds to one glioblastoma cell line that was found to be RT-PCR negative. Results shown here have been repeated three times.
Discussion
We have examined the expression of survivin in a large series of human brain tumors. We observed moderate to strong mRNA and protein expression in most biopsies from astrocytomas, oligodendrogliomas, meningiomas and schwannomas (Table 1) , whilst no expression was detectable in normal brain ( Figure 1D) and [2] . The most relevant finding of this study is the direct demonstration that tumor cells themselves express survivin, as assessed by mRNA and protein analysis of several cell lines and by immunohistochemistry of glioma, meningioma and schwannoma samples. These data confirm and extend the observations recently reported by Chakravarti et al. [12] . In their study, survivin positivity and high protein expression levels were suggested to be of unfavorable prognostic value. However, the method used (i.e. Western-blot) did not identify the cellular source of survivin expression, and it could not be excluded that glioma infiltrating lymphocytes could contribute to the positive Western-blot signals therefore distorting the prognostic factor analysis. Our data, by clearly identifying tumor cells as the main The prognosis of patients with brain tumors remains dismal despite huge efforts to improve surgical techniques, to use heavy particles for irradiation and to find new drugs. To devise new treatment strategies to target brain tumors is therefore a critical challenge for the next years. For gliomas, a major impediment to the success of therapy is their propensity to infiltrate normal structures, rendering demanding the specific targeting of malignant cells whilst sparing normal cells. Taking advantage of the natural migratory properties of immune cells and their anti-tumor activities, the fine manipulation of the immune system appears now as a promising new treatment avenue [15] . However, the specific targeting of tumor cells requires the characterization of the antigens that can be recognized by immune cells. For brain neoplasia, this research field is far less advanced than for melanoma. A few candidates have been suggested, but their real capabilities to elicit an immune response have rarely been explored [16, 17] . Considering its widespread expression pattern that we and others [12] have reported, survivin seems to be an interesting candidate to be examined. Indeed, its immunogenic properties have recently been evidenced in patients with non-CNS tumors. First, antibody reactivity against survivin was shown in the sera from some patients with lung or colorectal cancer [18] . Second, it was possible to generate in vitro survivin-specific CD8+ effector cells, and HLA-A2 restricted epitopes that are naturally processed have been identified [19] . Third, in an elegant series of experiments using multimeric survivin peptide/MHC complexes, Anderson et al. [20] showed spontaneous MHC-restricted response against survivin epitopes both in situ and ex vivo in breast cancer, leukemia and melanoma patients. Finally, the same authors reported that survivin specific T cells isolated by magnetic beads coated with multimers were able to lyse HLA-matched tumors originating form diverse tissue types [21] .
Overall, these data indicate that the eliciting or reinforcement of specific immune response against survivin is a promising approach for immunotherapies designed for brain tumors. However, the clinical development should be performed with caution, considering recent results showing that survivin may also be expressed in activated T cells, CD34 + cells, as well as stem cell populations that are involved in the renewal process of normal human colonic mucosa [2, 13, 22, 23] . 
